

CITATION REPORT

List of articles citing

Nanoparticles target distinct dendritic cell populations according to their size

DOI: 10.1002/eji.200737984

European Journal of Immunology, 2008, 38, 1404-13.

Source: <https://exaly.com/paper-pdf/43425464/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1003	Enhanced capacity of antigen presentation of HBc-VLP-pulsed RAW264.7 cells revealed by proteomics analysis. 2008 , 7, 4898-903		8
1002	Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. 2008 , 8, 764-75		203
1001	Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. 2008 , 283, 33508-15		20
1000	A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. 2009 , 183, 7268-77		128
999	Lipid-coated biodegradable particles as synthetic pathogens for vaccine engineering. 2009 ,		2
998	Quantitative determination of skin penetration of PEG-coated CdSe quantum dots in dermabraded but not intact SKH-1 hairless mouse skin. 2009 , 111, 37-48		78
997	Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsized target cells. 2009 , 239, 306-19		75
996	PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. 2009 , 140, 108-16		110
995	A novel vaccine adjuvant for recombinant flu antigens. 2009 , 37, 141-7		19
994	Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. <i>European Journal of Immunology</i> , 2009 , 39, 2809-21	6.1	52
993	Probing cell-type-specific intracellular nanoscale barriers using size-tuned quantum dots. 2009 , 5, 2581-8		61
992	Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. 2009 , 39, 562-70		168
991	Evaluation of nanoparticle immunotoxicity. 2009 , 4, 411-4		306
990	Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. 2009 , 64, 1003-13		65
989	Microneedle mediated delivery of nanoparticles into human skin. 2009 , 366, 190-200		120
988	Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. 2009 , 375, 148-54		37
987	Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. 2009 , 27, 5284-91		49

986	Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. 2009 , 27, 4784-90	92
985	Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron. 2009 , 27, 7385-93	16
984	Virus-like particle vaccines and adjuvants: the HPV paradigm. 2009 , 8, 1379-98	30
983	Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. 2009 , 32, 118-28	102
982	Intralymphatic immunotherapy. 2009 , 9, 537-43	63
981	Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. 2009 , 32, 895-906	12
980	Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. 2010 , 33, 848-58	111
979	Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. 2010 , 62, 362-74	547
978	Application of nanotechnologies for improved immune response against infectious diseases in the developing world. 2010 , 62, 378-93	96
977	Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. 2010 , 141, 93-100	63
976	Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length. 2010 , 142, 229-37	56
975	Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. 2010 , 144, 118-26	218
974	Nano is better than micro for targeted vaccine delivery. 2010 , 144, 117	3
973	Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. 2010 , 147, 342-9	167
972	Applications of nanoparticles in ophthalmology. 2010 , 29, 596-609	257
971	Ease of synthesis, controllable sizes, and in vivo large-animal-lymph migration of polymeric nanoparticles. 2010 , 5, 1435-8	19
970	Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. 2010 , 6, 523-9	126
969	Preservation of dendritic cell function upon labeling with amino functionalized polymeric nanoparticles. 2010 , 31, 7086-95	17

968	Modulation of immune response by combined targeting of complement receptors and low-affinity Fcγ receptors. 2010 , 130, 66-73	7
967	Cellular association and assembly of a multistage delivery system. 2010 , 6, 1329-40	86
966	B cell follicles and antigen encounters of the third kind. 2010 , 11, 989-96	225
965	Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. 2010 , 10, 787-96	1232
964	Nuevos esquemas de inmunoterapia específicas con alérgenos. 2010 , 30, 440	
963	The impact of nanomaterials in immune system. 2010 , 10, 85-91	30
962	Structure of Penaeus stylirostris densovirus, a shrimp pathogen. 2010 , 84, 11289-96	34
961	In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity. 2010 , 18, 1046-53	20
960	Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. 2010 , 21, 195101	115
959	Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. 2010 , 50, 63-88	197
958	Nanoparticles and the immune system. 2010 , 151, 458-65	619
957	Internalisation of hybrid titanium dioxide/para-amino benzoic acid nanoparticles in human dendritic cells did not induce toxicity and changes in their functions. 2010 , 199, 34-42	21
956	The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. 2010 , 28, 6597-602	48
955	Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. 2010 , 9, 1095-107	378
954	Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?. 2010 , 7, 2207-15	45
953	Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. 2011 , 89, 681-8	59
952	Liposomal vaccine delivery systems. 2011 , 8, 505-19	104
951	The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. 2011 , 10, 1731-42	87

950	Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. 2011 , 2, 1057-77	87
949	Poly(2-aminoethyl methacrylate) with well-defined chain length for DNA vaccine delivery to dendritic cells. 2011 , 12, 4373-85	47
948	Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. 2011 , 78, 107-16	65
947	Proteomic analysis of early response lymph node proteins in mice treated with titanium dioxide nanoparticles. 2011 , 74, 2745-59	33
946	Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. 2011 , 29, 6379-91	46
945	Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. 2011 , 23, 12-20	96
944	Cellular uptake mechanisms and toxicity of quantum dots in dendritic cells. 2011 , 6, 777-91	70
943	Present status of nanoparticle research for treatment of tuberculosis. 2011 , 14, 100-16	48
942	Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. 2011 , 118, 6836-44	147
941	Antibody co-targeting of DCs. 2011 , 118, 6726-7	2
940	Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against <i>Leishmania major</i> infection in C57BL/6 mice. 2011 , 33, 335-48	26
939	Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. 2011 , 41, 1305-12	109
938	Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. 2011 , 11, 2582-92	46
937	In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines. 2011 , 6, 466-477	55
936	The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. 2011 , 154, 131-7	84
935	Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. 2011 , 156, 154-60	74
934	Inhibiting angiogenesis by oral immunisation with poly(ϵ -caprolactone)-poly(ethylene glycol)-poly(ϵ -caprolactone) nanoparticle-encapsulated basic fibroblast growth factor. 2011 , 6, 221	3
933	The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. 2011 , 32, 6791-803	131

932	Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells. 2011 , 5, 606-21	81
931	Bio-inspired, bioengineered and biomimetic drug delivery carriers. 2011 , 10, 521-35	866
930	Designing polymeric particles for antigen delivery. 2011 , 40, 320-39	116
929	Developments in virus-like particle-based vaccines for infectious diseases and cancer. 2011 , 10, 1569-83	62
928	Influenza virosomes as a vaccine adjuvant and carrier system. 2011 , 10, 437-46	73
927	Trafficking of a dual-modality magnetic resonance and fluorescence imaging superparamagnetic iron oxide-based nanoprobe to lymph nodes. 2011 , 13, 1163-72	20
926	Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. 2011 , 3, 222-34	35
925	Stabilization of virus-like particles with poly(2-oxazoline)s. 2011 , 50, 2601-5	75
924	Engineered synthetic virus-like particles and their use in vaccine delivery. 2011 , 12, 100-9	46
923	Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. 2011 , 32, 3666-78	185
922	Dendritic cell internalization of foam-structured fluorescent mesoporous silica nanoparticles. 2011 , 353, 156-62	16
921	Synthesis and characterization of new poly(ortho ester amidine) copolymers for nonviral gene delivery. 2011 , 52, 921-932	44
920	Intralymphatic immunotherapy: from the rationale to human applications. 2011 , 352, 71-84	27
919	Injectable nanotechnology. 2011 , 298-322	
918	An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines. 2011 , 2011, 181646	40
917	In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. 2011 , 108, 15745-50	177
916	CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. 2011 , 187, 2112-21	48
915	Engineering Interfaces for Infection Immunity. 2011 , 295-314	1

914	Lung B cells promote early pathogen dissemination and hasten death from inhalation anthrax. 2012 , 5, 444-54	11
913	Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. 2012 , 109, 1080-5	250
912	Application of polymeric nanoparticles in immunotherapy. 2012 , 12, 658-64	21
911	Adjuvants for immunotherapy. 2012 , 12, 648-57	49
910	New routes for allergen immunotherapy. 2012 , 8, 1525-33	26
909	Virus-Like Particles as Efficient Delivery Platform to Induce a Potent Immune Response. 2012 , 87-122	3
908	Incunabular immunological events in prion trafficking. 2012 , 2, 440	31
907	Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. 2012 , 119, 95-105	39
906	Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. 2012 , 9, 3442-51	45
905	The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. 2012 , 132, 403-9	60
904	Nanoparticle migration and delivery of Paclitaxel to regional lymph nodes in a large animal model. 2012 , 214, 328-37	31
903	Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. 2012 , 30, 7541-6	55
902	Engineering approaches to immunotherapy. 2012 , 4, 148rv9	173
901	A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. 2012 , 86, 11686-97	58
900	Clear and present danger? Engineered nanoparticles and the immune system. 2012 , 142, w13609	72
899	Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. <i>European Journal of Immunology</i> , 2012 , 42, 3049-61	6.1 139
898	Particulate transepithelial drug carriers: barriers and functional polymers. 2012 , 2, 10427	13
897	New Nanobiotechnological Strategies for the Development of Vectors for Cancer Vaccines. 2012 , 391-421	

896	Mucosal vaccine design and delivery. 2012 , 14, 17-46	135
895	Targeting nanoparticles to dendritic cells for immunotherapy. 2012 , 509, 143-63	90
894	Enzyme-linked immunosorbent assay of IL-8 production in response to silver nanoparticles. 2012 , 926, 131-9	4
893	Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization. 2012 , 8, 3210-7	30
892	Nanotechnology in Vaccine Development. 2012 , 82, 13-27	4
891	Biomineralization and size control of stable calcium phosphate core-protein shell nanoparticles: potential for vaccine applications. 2012 , 23, 610-7	44
890	Gene Vaccines. 2012 ,	2
889	Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. 2012 , 9, 81-90	69
888	Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. 2012 , 4, 276-95	29
887	Dendritic Cells Interactions with the Immune System ¶ Implications for Vaccine Development. 2012 ,	1
886	Interactions of nanomaterials with the immune system. 2012 , 4, 169-83	87
885	Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. 2012 , 11, 69-86	16
884	Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. 2012 , 64, 505-19	156
883	Control of size dispersity of chitosan biopolymer microparticles and nanoparticles to influence vaccine trafficking and cell uptake. 2012 , 100, 1859-67	20
882	Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. 2012 , 24, 3845-9	186
881	Engineering nano- and microparticles to tune immunity. 2012 , 24, 3724-46	298
880	Penetration of drugs through skin, a complex rate-controlling membrane. 2012 , 17, 156-165	156
879	Activation of invariant Natural Killer T lymphocytes in response to the β -galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. 2012 , 423, 45-54	36

878	Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. 2012 , 422, 356-63	49
877	Enhanced stability of horseradish peroxidase encapsulated in acetalated dextran microparticles stored outside cold chain conditions. 2012 , 431, 101-10	45
876	License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. 2012 , 45, 482-91	91
875	The phagocytosis of gas-filled microbubbles by human and murine antigen-presenting cells. 2012 , 33, 333-42	20
874	Gas-filled microbubble-mediated delivery of antigen and the induction of immune responses. 2012 , 33, 5935-46	23
873	Delivery of plant-made vaccines and therapeutics. 2012 , 30, 440-8	25
872	CemX peptide-carrying HBcAg virus-like particles induced antibodies that down-regulate mlgE-B lymphocytes. 2012 , 52, 190-9	5
871	Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo. 2012 , 160, 367-73	28
870	PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. 2012 , 159, 135-42	103
869	PLGA-based nanoparticles: an overview of biomedical applications. 2012 , 161, 505-22	2194
868	Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. 2012 , 162, 159-66	53
867	Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice. 2013 , 10, 108	13
866	Nanoengineering approaches to the design of artificial antigen-presenting cells. 2013 , 8, 1173-89	55
865	Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. 2013 ,	
864	Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. 2013 , 14, 2798-806	104
863	Applications of nanotechnology for immunology. 2013 , 13, 592-605	483
862	Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. <i>European Journal of Immunology</i> , 2013 , 43, 2554-65	6.1 118
861	Influenza virosomes as vaccine adjuvant and carrier system. 2013 , 12, 779-91	88

860	Nanoparticulated heat-stable (STa) and heat-labile B subunit (LTB) recombinant toxin improves vaccine protection against enterotoxigenic Escherichia coli challenge in mouse. 2013 , 115, 147-53	12
859	Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles. 2013 , 89, 162-8	22
858	Virus-induced humoral immunity: on how B cell responses are initiated. 2013 , 3, 357-62	61
857	The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. 2013 , 131, 866-74	129
856	Nanotechnology in Dermatology. 2013 ,	3
855	Immunotherapy of allergic rhinitis: new therapeutic opportunities with virus-like particles filled with CpG motifs. 2013 , 27, 206-12	16
854	Effect of copper nanoparticles on metabolic rate and development of chicken embryos. 2013 , 186, 125-129	30
853	Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. 2013 , 191, 5278-90	67
852	Convective diffusion of nanoparticles from the epithelial barrier toward regional lymph nodes. 2013 , 199-200, 23-43	29
851	Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis. 2013 , 10, 1045-55	62
850	Operationalization and application of "early warning signs" to screen nanomaterials for harmful properties. 2013 , 15, 190-203	19
849	Vaccine delivery carriers: insights and future perspectives. 2013 , 440, 27-38	83
848	Development of the vault particle as a platform technology. 2013 , 7, 889-902	64
847	Noninfectious disease vaccines. 2013 , 1138-1145	
846	Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. 2013 , 30, 325-41	61
845	Size effect of amphiphilic poly(Eglutamic acid) nanoparticles on cellular uptake and maturation of dendritic cells in vivo. 2013 , 9, 8894-901	41
844	The effect of vaccines based on ovalbumin coupled to gas-filled microbubbles for reducing infection by ovalbumin-expressing Listeria monocytogenes. 2013 , 34, 5423-30	9
843	On the efficacy of malaria DNA vaccination with magnetic gene vectors. 2013 , 168, 10-7	17

842	Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation. 2013 , 23, 168-77	29
841	Proposed mechanisms of action for prostate cancer vaccines. 2013 , 10, 149-60	14
840	Dendritic cell-based nanovaccines for cancer immunotherapy. 2013 , 25, 389-95	95
839	Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis. 2013 , 30, 1349-61	26
838	Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. 2013 , 31, 735-49	54
837	Materials based tumor immunotherapy vaccines. 2013 , 25, 238-45	49
836	Melanoma immunotherapy: historical precedents, recent successes and future prospects. 2013 , 5, 169-82	24
835	Nanoparticles, Immunomodulation and Vaccine Delivery. 2013 , 449-475	4
834	Nanoparticles and Antigenicity. 2013 , 547-579	1
833	Evaluating the Adverse Effects of Nanomaterials on the Immune System with Animal Models. 2013 , 639-670	1
832	Cytokines as biomarkers of nanoparticle immunotoxicity. 2013 , 42, 5552-76	259
831	Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes. 2013 , 49, 67-77	79
830	The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells. 2013 , 60, 275-83	18
829	Nanoparticulates. 2013 , 1373-1419	3
828	The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. 2013 , 4, 138	119
827	New approaches to transcutaneous immunotherapy: targeting dendritic cells with novel allergen conjugates. 2013 , 13, 669-76	12
826	VLPs and particle strategies for cancer vaccines. 2013 , 12, 1173-93	13
825	Targeting dendritic cells--why bother?. 2013 , 121, 2836-44	92

824	Nanoparticles and microparticles of polymers and polysaccharides to administer fish vaccines. 2013 , 46, 407-19	28
823	Particle platforms for cancer immunotherapy. 2013 , 8, 1683-96	47
822	Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. 2013 , 8, e61646	108
821	Nanocarrier-based immunotherapy in cancer management and research. 2014 , 3, 121-34	14
820	Size matters--nanotechnology and therapeutics in rheumatology and immunology. 2014 , 10, 11-21	11
819	Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines. 2014 , 2, 51-69	7
818	Nanoparticles in the Development of Therapeutic Cancer Vaccines. 2014 , 2, 2-22	5
817	Cationic Nanostructures for Vaccines. 2014 ,	5
816	. 2014 ,	0
815	Convective diffusion of nanoparticles to regional lymph nodes from the epithelial barrier. 2014 , 299-317	
814	Applications of nanomaterials as vaccine adjuvants. 2014 , 10, 2761-74	76
813	A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle. 2014 , 10, 64-72	35
812	The impact of size on particulate vaccine adjuvants. 2014 , 9, 2671-81	68
811	Antigen delivery by virus-like particles for immunotherapeutic vaccination. 2014 , 5, 1223-40	23
810	Nanotoxicology: Towards Safety by Design. 2014 , 391-424	4
809	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. 2014 , 10, 1059-67	25
808	Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung. 2014 , 9, 1857-68	25
807	Nano-Oncologicals. 2014 ,	4

806	Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration. 2014 , 103, 128-39	25
805	Engineered Cell Manipulation for Biomedical Application. 2014 ,	2
804	Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine. 2014 , 9, 2187-202	8
803	Entrapment in plasma microparticles: a promising strategy for antigen delivery. 2014 , 102, 1244-54	3
802	A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. 2014 , 16, 1194-203	36
801	Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies. 2014 , 9, e102235	5
800	Biodistribution and clearance of a filamentous plant virus in healthy and tumor-bearing mice. 2014 , 9, 221-235	48
799	Clinical relevance of novel imaging technologies for sentinel lymph node identification and staging. 2014 , 32, 269-79	42
798	A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation. 2014 , 468, 187-95	15
797	Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. 2014 , 191, 24-33	101
796	Just-in-time vaccines: Biom mineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. 2014 , 10, 571-8	32
795	Immunomodulatory properties of the vaccine adjuvant alum. 2014 , 28, 1-5	126
794	Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. 2014 , 28, 51-8	68
793	Targeted immunomodulation using antigen-conjugated nanoparticles. 2014 , 6, 298-315	26
792	Nanotoxicology. 2014 ,	14
791	Nanoparticle vaccines. 2014 , 32, 327-37	583
790	Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design. 2014 , 46, 8053-8068	6
789	HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis. 2014 , 32, 6240-50	27

788	Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection. 2014 , 477, 334-43	24
787	Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo. 2014 , 3, e173	49
786	Engaging adaptive immunity with biomaterials. 2014 , 2, 2409-2421	37
785	Functional nanomaterials can optimize the efficacy of vaccines. 2014 , 10, 4505-20	42
784	The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells. 2014 , 35, 8876-8886	24
783	Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. 2014 , 192, 209-18	145
782	Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory. 2014 , 32, 5475-83	61
781	Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity. 2014 , 11, 922-37	10
780	Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding. 2014 , 15, 2475-81	29
779	The right touch: design of artificial antigen-presenting cells to stimulate the immune system. 2014 , 5, 3355	28
778	Messenger RNA (mRNA) nanoparticle tumour vaccination. 2014 , 6, 7715-29	52
777	Biodistribution and clearance of a filamentous plant virus in healthy and tumor-bearing mice. 2014 , 9, 221-35	100
776	Enhanced in vivo targeting of murine nonparenchymal liver cells with monophosphoryl lipid A functionalized microcapsules. 2014 , 15, 2378-88	13
775	Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations. 2014 , 40, 1565-75	61
774	Nanoscale artificial antigen presenting cells for T cell immunotherapy. 2014 , 10, 119-29	84
773	Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. 2014 , 32, 2882-95	124
772	Design of magnetic polyplexes taken up efficiently by dendritic cell for enhanced DNA vaccine delivery. 2014 , 21, 212-8	38
771	Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy. 2014 , 3, 1194-9	67

770	Harnessing the exosome-induced immune response for cancer immunotherapy. 2014 , 28, 58-67	73
769	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. 2014 , 2, 105	125
768	Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms. 2014 , 3,	30
767	Particulate Matter-Induced Immune Activation. 2014 , 227-244	
766	Enhanced Immunostimulation with Crosslinked CpG-DNA/β1,3-Glucan Nanoparticle through Hybridization. 2014 , 43, 991-993	11
765	Nanotechnology for Multimodality Imaging: Applications in Disease Detection and Treatment Guidance. 2014 , 145-193	
764	Nanomedicines Targeting the Tumor Microenvironment. 2015 , 21, 314-21	53
763	Production of Virus-Like Particles in Plants. 2015 , 272-283	
762	Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice. 2015 , 5, 14274	32
761	X-Ray Analysis of Viral Nanoparticles. 2015 , 82-95	3
760	Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8+ T cell responses after nanoparticle vaccination. 2015 , e52771	10
759	A thermostable, chromatographically purified Ebola nano-VLP vaccine. 2015 , 13, 228	9
758	Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport. 2015 , 74, 333-44	9
757	Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. 2015 , 112, 1102-10	21
756	Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo. 2015 , 33, 292-6	9
755	3.5 Current Trends and Developments for Nanotechnology in Cancer. 2015 , 290-342	
754	Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model. 2015 , 12, 3-8	23
753	The Use of Synthetic Carriers in Malaria Vaccine Design. 2015 , 3, 894-929	17

752	Small Wonders-The Use of Nanoparticles for Delivering Antigen. 2015 , 3, 638-61	19
751	Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease. 2015 , 3, 829-49	12
750	Per-oral immunization with antigen-conjugated nanoparticles followed by sub-cutaneous boosting immunization induces long-lasting mucosal and systemic antibody responses in mice. 2015 , 10, e0118067	8
749	Head-to-Head Comparison of Soluble vs. Q β VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. 2015 , 10, e0142035	22
748	The Application of Liposomes as Vaccine Adjuvants. 2015 , 77-94	3
747	The potential of nanoparticles for the immunization against viral infections. 2015 , 3, 4767-4779	40
746	Virus-Like Particles, a Versatile Subunit Vaccine Platform. 2015 , 159-180	10
745	Parenteral Vaccine Administration: Tried and True. 2015 , 261-286	3
744	Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP). 2015 , 29, 3817-27	10
743	Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses. 2015 , 200, 1-12	68
742	Nano-TiO ₂ modulates the dermal sensitization potency of dinitrochlorobenzene after topical exposure. 2015 , 172, 392-9	21
741	The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance. 2015 , 104, 1352-61	29
740	Nanoparticle-based autoimmune disease therapy. 2015 , 160, 3-13	67
739	Development of virus-like particles for diagnostic and prophylactic biomedical applications. 2015 , 7, 722-35	57
738	Is The Allergen Really Needed in Allergy Immunotherapy?. 2015 , 2, 72-82	32
737	Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. 2015 , 11, 1097-107	13
736	Synthetic Nanoparticles for Vaccines and Immunotherapy. 2015 , 115, 11109-46	502
735	Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma. 2015 , 9, 6918-33	242

734	Engineered Materials for Cancer Immunotherapy. 2015 , 10, 511-531	76
733	Engineering New Approaches to Cancer Vaccines. 2015 , 3, 836-43	42
732	Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines. 2015 , 33, 2903-8	30
731	Chemokine-Releasing Nanoparticles for Manipulation of Lymph Node Microenvironment. 2015 , 5, 298-320	8
730	Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles. 2015 , 10, 915-29	9
729	Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases. 2015 , 11, 650-6	22
728	Intralymphatic immunotherapy. 2015 , 8, 9	34
727	Guiding principles in the design of molecular bioconjugates for vaccine applications. 2015 , 26, 791-801	62
726	Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. 2015 , 12, 1356-65	80
725	Reduction-Sensitive Dextran Nanogels Aimed for Intracellular Delivery of Antigens. 2015 , 25, 2993-3003	70
724	Biomaterial Strategies for Immunomodulation. 2015 , 17, 317-49	110
723	Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. 2015 , 33, 5578-5587	49
722	Design and evaluation of surface and adjuvant modified PLGA microspheres for uptake by dendritic cells to improve vaccine responses. 2015 , 496, 371-81	22
721	In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. 2015 , 33, 1201-10	280
720	Biomimetic particles as therapeutics. 2015 , 33, 514-524	71
719	From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. 2015 , 14, 781-803	336
718	Shape and size-dependent immune response to antigen-carrying nanoparticles. 2015 , 220, 141-148	180
717	Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis. 2015 , 495, 849-61	19

716	Nanoparticulate immunotherapy for cancer. 2015 , 219, 167-180	64
715	Control of polymeric nanoparticle size to improve therapeutic delivery. 2015 , 219, 536-547	174
714	Cationic micelle based vaccine induced potent humoral immune response through enhancing antigen uptake and formation of germinal center. 2015 , 135, 556-564	11
713	Multi-enveloping of particulated antigens with biopolymers and immunostimulant polynucleotides. 2015 , 30, 424-434	13
712	Engineering opportunities in cancer immunotherapy. 2015 , 112, 14467-72	90
711	Epsilon-caprolactone modified polyethylenimine for highly efficient antigen delivery and chemical exchange saturation transfer functional MR imaging. 2015 , 56, 219-28	9
710	Assessment of the enhancement of PLGA nanoparticle uptake by dendritic cells through the addition of natural receptor ligands and monoclonal antibody. 2015 , 33, 6588-95	14
709	CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. 2015 , 40, 88-97	197
708	Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells. 2015 , 43, 1-12	90
707	Physical and Biophysical Characteristics of Nanoparticles: Potential Impact on Targeted Drug Delivery. 2015 , 649-666	1
706	Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. 2015 , 58, 888-96	46
705	Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery. 2015 , 7, 65-74	67
704	Nanoparticle-based immunotherapy for cancer. 2015 , 9, 16-30	322
703	Subunit Vaccine Delivery. 2015 ,	4
702	Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation. 2015 , 32, 1341-53	35
701	Vaccine adjuvant uses of poly-IC and derivatives. 2015 , 14, 447-59	118
700	Molecular characterization of strains of decapod penstyldensovirus 1 (PstDV1) isolated in farmed <i>Litopenaeus vannamei</i> from Venezuela. 2015 , 436, 34-39	5
699	Linking form to function: Biophysical aspects of artificial antigen presenting cell design. 2015 , 1853, 781-90	36

698	Beyond antigens and adjuvants: formulating future vaccines. 2016 , 126, 799-808	216
697	Recent Advances in Subunit Vaccine Carriers. 2016 , 4,	144
696	Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. 2016 , 4,	22
695	Oxidative Burst-Dependent NETosis Is Implicated in the Resolution of Necrosis-Associated Sterile Inflammation. 2016 , 7, 557	38
694	Chemokine-Releasing Microparticles Improve Bacterial Clearance and Survival of Anthrax Spore-Challenged Mice. 2016 , 11, e0163163	4
693	Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. 2016 , 4,	71
692	Virus-based nanoparticles as platform technologies for modern vaccines. 2016 , 8, 554-78	46
691	Multifunctional Nanostructures for Tumor-Targeted Molecular Imaging and Photodynamic Therapy. 2016 , 5, 311-8	15
690	Evaluating the Interactions Between Proteins and Components of the Immune System with Polymer Nanoparticles. 2016 , 221-289	
689	Nanoparticles and direct immunosuppression. 2016 , 241, 1064-73	44
688	Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines. 2016 , 234, 124-34	131
687	Evaluating the Adverse Effects of Nanomaterials on the Immune System with Animal Models. 2016 , 281-315	
686	Immune Tolerance for Autoimmune Disease and Cell Transplantation. 2016 , 18, 181-205	53
685	Engineering virus-like particles as vaccine platforms. 2016 , 18, 44-9	114
684	Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen. 2016 , 27, 1293-304	10
683	mRNA vaccine delivery using lipid nanoparticles. 2016 , 7, 319-34	241
682	Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. 2016 , 512, 147-157	25
681	Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against <i>Toxoplasma gondii</i> . 2016 , 170, 236-246	21

680	Drug Delivery to the Lymphatic System. 2016 , 503-548	1
679	Liposomal constructs for antitumoral vaccination by the nasal route. 2016 , 130, 14-22	9
678	Overview on experimental models of interactions between nanoparticles and the immune system. 2016 , 83, 1365-1378	56
677	The Density Code for the Development of a Vaccine?. 2016 , 105, 3223-3232	15
676	Critical review of the safety assessment of nano-structured silica additives in food. 2016 , 14, 44	74
675	Nanomedicine. 2016 , 251-274	1
674	Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy. 2016 , 6, 35182	40
673	TB trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice. 2016 , 21, 653-658	9
672	Optimization of protein loaded PLGA nanoparticle manufacturing parameters following a quality-by-design approach. 2016 , 6, 104502-104512	6
671	Modulation of Immune Responses by Particulate Materials. 2016 , 28, 5525-41	51
670	Adjuvant effect of B domain of staphylococcal protein A displayed on the surface of hepatitis B virus capsid. 2016 , 113, 268-74	5
669	Subtumoral analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle properties. 2016 , 12, 1053-1062	22
668	PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. 2016 , 12, 1056-69	116
667	Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge. 2016 , 60, 2052-62	13
666	Designing liposomal adjuvants for the next generation of vaccines. 2016 , 99, 85-96	66
665	Biologics to Treat Substance Use Disorders. 2016 ,	3
664	New Strategies in Cancer Nanomedicine. 2016 , 56, 41-57	84
663	Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery. 2016 , 8, 938-48	73

662	A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys. 2016 , 196, 284-97	22
661	Engineering immunity in the mucosal niche against sexually transmitted infections. 2016 , 8, 107-22	1
660	Biomaterials for enhancing anti-cancer immunity. 2016 , 40, 1-8	94
659	Environmental Influences on the Immune System. 2016 ,	5
658	Engineered Nanoparticles and the Immune System: Interaction and Consequences. 2016 , 205-226	1
657	A Generic Polymer-Protein Ligation Strategy for Vaccine Delivery. 2016 , 17, 874-81	9
656	Nanomaterial-dependent immunoregulation of dendritic cells and its effects on biological activities of contraceptive nanovaccines. 2016 , 225, 252-68	12
655	Nanoparticles, Immunomodulation and Vaccine Delivery. 2016 , 101-127	
654	Nanoparticles and Antigenicity. 2016 , 271-307	
653	Advances in Therapeutic Cancer Vaccines. 2016 , 130, 191-249	71
652	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. 2016 , 16, 56-66	266
651	Current understanding of interactions between nanoparticles and the immune system. 2016 , 299, 78-89	173
650	Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes. 2016 , 10, 1602-18	67
649	Nanoparticle-Based Nicotine Vaccine. 2016 , 249-278	2
648	Synthetic Polymeric Nanoparticles for Immunomodulation. 2016 , 413-438	1
647	Peptide/protein vaccine delivery system based on PLGA particles. 2016 , 12, 806-28	110
646	Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. 2016 , 74, 231-44	27
645	Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. 2016 , 12, 740-8	27

644	Preclinical safety study of a recombinant <i>Streptococcus pyogenes</i> vaccine formulated with aluminum adjuvant. 2017 , 37, 222-230	11
643	Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. 2017 , 113, 61-86	49
642	Tailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines. 2017 , 122, 105-113	74
641	Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. 2017 , 11, 54-68	119
640	Nanomedicine approaches to improve cancer immunotherapy. 2017 , 9, e1456	29
639	Newcastle disease virus-like particles induce DC maturation through TLR4/NF- κ B pathway and facilitate DC migration by CCR7-CCL19/CCL21 axis. 2017 , 203, 158-166	18
638	Nano-ophthalmology: Applications and considerations. 2017 , 13, 1459-1472	55
637	Exploiting virus-like particles as innovative vaccines against emerging viral infections. 2017 , 55, 220-230	41
636	Type I Interferons Modulate CD8 T Cell Immunity to mRNA Vaccines. 2017 , 23, 216-226	51
635	Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. 2017 , 251, 92-100	50
634	Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives. 2017 , 14, 1407-1422	52
633	Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs. 2017 , 13, 2015-2025	18
632	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. 2017 , 256, 26-45	27
631	Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs. 2017 , 189, 331-341	25
630	Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. 2017 , 256, 56-67	82
629	Safety assessments of subcutaneous doses of aragonite calcium carbonate nanocrystals in rats. 2017 , 19, 175	12
628	PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8 T cell responses. 2017 , 137, 61-72	25
627	Vaccination Against Fungal Diseases: Lessons from <i>Candida albicans</i> . 2017 , 207-242	

626	Bioengineering bacterial outer membrane vesicles as vaccine platform. 2017 , 35, 565-574	115
625	Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity. 2017 , 375, 48-57	65
624	Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. 2017 , 11, 5417-5429	96
623	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. 2017 , 29, 1606036	178
622	New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. 2017 , 24, 233-243	61
621	Immunogenetics of Fungal Diseases. 2017 ,	1
620	Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells. 2017 , 3, 496-501	21
619	Synthetic nanovaccines for immunotherapy. 2017 , 263, 200-210	65
618	The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation. 2017 , 7, 736	12
617	Platform technologies for modern vaccine manufacturing. 2017 , 35, 4480-4485	31
616	Porcine epidemic diarrhea virus virus-like particles produced in insect cells induce specific immune responses in mice. 2017 , 53, 548-554	11
615	Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. 2017 , 132, 48-58	38
614	An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators. 2017 , 16, 491-502	25
613	Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology. 2017 , 97, 1-60	62
612	Co-Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis. 2017 , 1, 1700022	10
611	Gene transfection efficiency into dendritic cells is influenced by the size of cationic liposomes/DNA complexes. 2017 , 102, 230-236	28
610	Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing. 2017 , 5, 223-233	55
609	Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation. 2017 , 14, 328-335	11

608	Acetalated Dextran: A Tunable and Acid-Labile Biopolymer with Facile Synthesis and a Range of Applications. 2017 , 117, 1915-1926	77
607	Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers. 2017 , 121, 15-27	70
606	Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size. 2017 , 3, 153-159	49
605	Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. 2017 , 247, 194-205	69
604	Adjuvant Activity Enhanced by Cross-Linked CpG-Oligonucleotides in β Glucan Nanogel and Its Antitumor Effect. 2017 , 28, 565-573	32
603	Aerosol Delivery of Functionalized Gold Nanoparticles Target and Activate Dendritic Cells in a 3D Lung Cellular Model. 2017 , 11, 375-383	37
602	Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles. 2017 , 266, 109-118	85
601	Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine. 2017 , 7, 12580	19
600	Effects of engineered nanoparticles on the innate immune system. 2017 , 34, 25-32	102
599	Nanoparticulate Immunotherapy: An Intelligent Way to Tailor Make Our Defense System. 2017 , 419-451	
598	Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. 2017 , 64, 237-248	35
597	Nanoparticles and innate immunity: new perspectives on host defence. 2017 , 34, 33-51	160
596	Nanomaterials for cancer immunotherapy. 2017 , 148, 16-30	173
595	Liposomal β galactosylceramide is taken up by gut-associated lymphoid tissue and stimulates local and systemic immune responses. 2017 , 69, 1724-1735	4
594	Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium. 2017 , 266, 27-35	39
593	Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation. 2017 , 34, 3-24	44
592	Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics. 2017 , 12, 2349-2365	43
591	Major findings and recent advances in virus-like particle (VLP)-based vaccines. 2017 , 34, 123-132	233

590	Engineering biodegradable guanidyl-decorated PEG-PCL nanoparticles as robust exogenous activators of DCs and antigen cross-presentation. 2017 , 9, 13413-13418	18
589	Nanoparticle Surface Functionality Dictates Cellular and Systemic Toxicity. 2017 , 29, 6578-6595	73
588	Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. 2017 , 16, 883-894	34
587	Highlights in nanocarriers for the treatment against cervical cancer. 2017 , 80, 748-759	25
586	Calcium phosphate nanoparticles as a new generation vaccine adjuvant. 2017 , 16, 895-906	35
585	Tolerogenic Nanoparticles to Treat Islet Autoimmunity. 2017 , 17, 84	17
584	STIM1 promotes migration, phagosomal maturation and antigen cross-presentation in dendritic cells. 2017 , 8, 1852	31
583	Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy. 2017 , 28, 1993-2000	30
582	Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges. 2017 , 114, 43-59	66
581	The era of bioengineering: how will this affect the next generation of cancer immunotherapy?. 2017 , 15, 142	10
580	Immunogenicity of antigen-conjugated biodegradable polydiacetylene liposomes administered mucosally. 2017 , 105, 557-565	3
579	Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. 2017 , 113, 191-202	157
578	Poly(lactic acid)-based particulate systems are promising tools for immune modulation. 2017 , 48, 41-57	68
577	Polymers for DNA Vaccine Delivery. 2017 , 3, 108-125	28
576	Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. 2017 , 47, 11-18	27
575	Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. 2017 , 17, 1326-1335	302
574	Particulate Technology for Delivery of Therapeutics. 2017 ,	4
573	Regulatory Development of Nanotechnology-Based Vaccines. 2017 , 393-410	2

572	Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen. 2017 , 12, 8377-8388	16
571	Harnessing Nanoparticles for Immunomodulation and Vaccines. 2017 , 5,	77
570	Nanomaterials Based on Lipids for Vaccine Development. 2017 , 241-257	5
569	Inflammatory/Noninflammatory Adjuvants and Nanotechnology—The Secret to Vaccine Design. 2017 , 99-125	1
568	Microparticles and Nanoparticles for Cancer-Targeting Vaccines. 2017 , 171-183	1
567	Current applications and future prospects of nanomaterials in tumor therapy. 2017 , 12, 1815-1825	49
566	Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. 2017 , 8, 226	30
565	Why the Immune System Should Be Concerned by Nanomaterials?. 2017 , 8, 544	45
564	4.21 Engineering Interfaces for Infection Immunity ?. 2017 , 381-403	
563	Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation. 2017 , 1, 244-260	73
562	A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling. 2017 , 15, 54	28
561	The Versatile Dioctadecyldimethylammonium Bromide. 2017 ,	2
560	Entrapment of LTB protein in alginate nanoparticles protects against Enterotoxigenic Escherichia coli. 2018 , 126, 320-328	8
559	Biomaterials for Engineering Immune Responses. 2018 , 98, 49-68	0
558	Immunomodulatory activity of curcumin-entrapped poly d,l-lactic--glycolic acid nanoparticles in mice. 2018 , 7, 168-175	22
557	Potency of a Scalable Nanoparticulate Subunit Vaccine. 2018 , 18, 3007-3016	39
556	Immunostimulation and Immunosuppression: Nanotechnology on the Brink. 2018 , 2, 1700347	24
555	Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine. 2018 , 29, 776-785	19

554	Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. 2018 , 273, 147-159	47
553	Application of nanomaterials in cancer immunotherapy. 2018 , 7, 53-64	51
552	Polymer Assembly Encapsulation of Lanthanide Nanoparticles as Contrast Agents for In Vivo Micro-CT. 2018 , 19, 896-905	8
551	Preparation of virus-like particles for porcine circovirus type 2 by YeastFab Assembly. 2018 , 54, 246-255	6
550	Combined use of nanocarriers and physical methods for percutaneous penetration enhancement. 2018 , 127, 58-84	48
549	Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulators to lymph nodes. 2018 , 162, 71-81	27
548	Immune responses to engineered nanomaterials: current understanding and challenges. 2018 , 10, 8-14	34
547	Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System. 2018 , 15, 508-518	26
546	Engineered hybrid spider silk particles as delivery system for peptide vaccines. 2018 , 172, 105-115	31
545	Nanoparticles for dendritic cell-based immunotherapy. 2018 , 542, 253-265	41
544	Adjuvants for Animal Vaccines. 2018 , 31, 11-22	33
543	Recent Advances in Application of Nanoparticles in Fish Vaccine Delivery. 2018 , 26, 29-41	29
542	Analysis of Nanoparticle-Adjuvant Properties In Vivo. 2018 , 1682, 189-195	3
541	Characterization of Nanoparticles Intended for Drug Delivery. 2018 ,	3
540	Copper nanoparticles as an alternative feed additive in poultry diet: a review. 2018 , 7, 69-93	42
539	Engineering detoxified pneumococcal pneumolysin derivative A146PLY for self-biomineralization of calcium phosphate: Assessment of their protective efficacy in murine infection models. 2018 , 155, 152-164	4
538	Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses. 2018 , 156, 194-203	35
537	Clay Nanoparticles Elicit Long-Term Immune Responses by Forming Biodegradable Depots for Sustained Antigen Stimulation. 2018 , 14, e1704465	27

536	Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy. 2018 , 10, 20851-20862	45
535	Rational Design and In Vivo Characterization of Vaccine Adjuvants. 2018 , 59, 309-322	2
534	Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action. 2018 , 14, 80	38
533	A Perspective on Nanoparticle Universal Influenza Vaccines. 2018 , 4, 1656-1665	18
532	Virus-like particles in der Prophylaxe und Immuntherapie allergischer Erkrankungen. 2018 , 27, 22-33	
531	A Novel Cellular Pathway of Antigen Presentation and CD4 T Cell Activation. 2018 , 9, 2684	6
530	Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy. 2018 , 30, 63-69	35
529	Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy. 2018 , 289, 114-124	33
528	New opportunities for nanoparticles in cancer immunotherapy. 2018 , 22, 24	77
527	A systematic electron microscopic study on the uptake of barium sulphate nano-, submicro-, microparticles by bone marrow-derived phagocytosing cells. 2018 , 80, 352-363	7
526	Nanoparticle Vaccines Against Infectious Diseases. 2018 , 9, 2224	204
525	PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia. 2018 , 36, 6926-6932	18
524	A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses. 2018 , 10, 35745-35759	10
523	Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy. 2018 , 8, 404	64
522	Recent exploration of bio-mimetic nanomaterial for potential biomedical applications. 2018 , 93, 1104-1115	17
521	Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity. 2018 , 10, 33532-33544	30
520	Virus-like particle vaccines: immunology and formulation for clinical translation. 2018 , 17, 833-849	64
519	Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. 2018 , 12, 5121-5129	303

518	Development of mRNA vaccines and their prophylactic and therapeutic applications. 2018 , 11, 5173-5192	10
517	Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. 2018 , 130, 50-57	47
516	Lipid nanoparticles. 2018 , 749-783	4
515	Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant. 2018 , 14, 2786-2801	16
514	Unintended effects of drug carriers: Big issues of small particles. 2018 , 130, 90-112	35
513	Critical micelle concentration and particle size determine adjuvanticity of cyclic lipopeptides. 2018 , 88, e12698	4
512	DNA and mRNA vaccination against allergies. 2018 , 29, 679-688	35
511	Tunable aggregation of gold-silica janus nanoparticles to enable contrast-enhanced multiwavelength photoacoustic imaging in vivo. 2018 , 10, 15365-15370	29
510	Microneedle arrays for vaccine delivery: the possibilities, challenges and use of nanoparticles as a combinatorial approach for enhanced vaccine immunogenicity. 2018 , 15, 851-867	30
509	Top-down fabrication of shape-controlled, monodisperse nanoparticles for biomedical applications. 2018 , 132, 169-187	68
508	Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. 2018 , 6,	64
507	Prevention of Type 1 Diabetes with Acetalated Dextran Microparticles Containing Rapamycin and Pancreatic Peptide P31. 2018 , 7, e1800341	15
506	Clinical applications of nanostructured drug delivery systems. 2018 , 43-116	3
505	The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases. 2018 , 9, 155	106
504	Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance. 2018 , 9, 230	88
503	Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides. 2018 , 9, 783	14
502	Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). 2018 , 9, 898	8
501	An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia. 2018 , 9, 1195	11

500	Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. 2018 , 27, 245-255	23
499	Lipid-Based Nanoparticles as a Potential Delivery Approach in the Treatment of Rheumatoid Arthritis. 2018 , 8,	59
498	Disease-Triggered Drug Release Effectively Prevents Acute Inflammatory Flare-Ups, Achieving Reduced Dosing. 2018 , 14, e1800703	10
497	Critical review of the safety assessment of titanium dioxide additives in food. 2018 , 16, 51	98
496	Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. 2018 , 9, 1499	74
495	Lymphatic Transport and Lymph Node Location of Microspheres Subcutaneously Injected in the Vicinity of Tumors in a Rabbit Model of Breast Cancer. 2018 , 35, 191	2
494	Engineering Platforms for T Cell Modulation. 2018 , 341, 277-362	8
493	Engineered nanomaterials for their applications in theragnostics. 2018 , 66, 20-28	8
492	Porous Silicon Particles for Cancer Therapy and Bioimaging. 2018 , 305-340	3
491	Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. 2018 , 13, e0197694	14
490	Immunogenicity of diphtheria toxoid and poly(I:C) loaded cationic liposomes after hollow microneedle-mediated intradermal injection in mice. 2018 , 547, 250-257	17
489	Size-Controlled Iron Oxide Nanoplatfoms with Lipidoid-Stabilized Shells for Efficient Magnetic Resonance Imaging-Trackable Lymph Node Targeting and High-Capacity Biomolecule Display. 2018 , 10, 20281-20295	22
488	Biomedical Applications. 2018 , 659-682	
487	Production of complex viral glycoproteins in plants as vaccine immunogens. 2018 , 16, 1531	45
486	Tailoring inorganic nanoadjuvants towards next-generation vaccines. 2018 , 47, 4954-4980	53
485	Noninfectious Disease Vaccines. 2018 , 689-697.e4	1
484	Materials-Based Cancer Immunotherapies. 2019 , 715-739	1
483	Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. 2019 , 145, 57-72	48

482	Codelivery of mRNA with β -Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration. 2019 , 4, 13015-13026	21
481	Electrospray for generation of drug delivery and vaccine particles applied in vitro and in vivo. 2019 , 105, 110070	33
480	Immunotoxicity Considerations for Next Generation Cancer Nanomedicines. 2019 , 6, 1900133	27
479	The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. 2019 , 7,	4
478	Self-Assembling Peptides for Vaccine Development and Antibody Production. 2019 , 1-21	
477	Silver nanoparticle immunomodulatory potential in absence of direct cytotoxicity in RAW 264.7 macrophages and MPRO 2.1 neutrophils. 2019 , 16, 63-73	14
476	Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. 2019 , 7,	25
475	Therapeutic delivery to the peritoneal lymphatics: Current understanding, potential treatment benefits and future prospects. 2019 , 567, 118456	9
474	Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model. 2019 , 37, 7256-7268	9
473	Physical and chemical profiles of nanoparticles for lymphatic targeting. 2019 , 151-152, 72-93	37
472	Three decades of messenger RNA vaccine development. 2019 , 28, 100766	98
471	Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size. 2019 , 29, 1903391	23
470	A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: Formulation, cellular uptake and biodistribution investigations. 2019 , 143, 51-60	24
469	Effects of the Japanese Encephalitis Virus Genotype V-Derived Sub-Viral Particles on the Immunogenicity of the Vaccine Characterized by a Novel Virus-Like Particle-Based Assay. 2019 , 7,	3
468	Evaluation of immunologic and intestinal effects in rats administered an E 171-containing diet, a food grade titanium dioxide (TiO). 2019 , 133, 110793	22
467	Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (β amino ester) nano-vaccines for melanoma. 2019 , 22, 102092	5
466	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. 2019 , 10, 4272	80
465	Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease. 2019 , 20,	51

464	Polymeric micro- and nanoparticles for immune modulation. 2018 , 7, 14-30	43
463	Critical Size Limit of Biodegradable Nanoparticles for Enhanced Lymph Node Trafficking and Paracortex Penetration. 2019 , 12, 837-844	39
462	A Viral Nanoparticle Cancer Vaccine Delays Tumor Progression and Prolongs Survival in a HER2 Tumor Mouse Model. 2019 , 2, 1800139	17
461	Color-coded perfluorocarbon nanodroplets for multiplexed ultrasound and Photoacoustic imaging. 2019 , 12, 741-747	12
460	Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes. 2019 , 7, 822-835	17
459	A Novel Polysaccharide Carrier for Functional Oligonucleotides: Immunocyte Targeting through EGlucan Receptors. 2019 , 79-92	2
458	Rod-Scale Design Strategies for Immune-Targeted Delivery System toward Cancer Immunotherapy. 2019 , 13, 7705-7715	19
457	Particle size analyses of polydisperse liposome formulations with a novel multispectral advanced nanoparticle tracking technology. 2019 , 566, 680-686	13
456	Real-Time Imaging of Vaccine Biodistribution Using Zwitterionic NIR Nanoparticles. 2019 , 8, e1900035	6
455	HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions. 2019 , 11,	10
454	Combinatorial, Microparticle-Based Delivery of Immune Modulators Reprograms the Dendritic Cell Phenotype and Promotes Remission of Collagen-Induced Arthritis in Mice.. 2019 , 2, 2388-2404	15
453	Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. 2019 , 140, 29-39	16
452	Acute B-Cell Inhibition by Soluble Antigen Arrays Is Valency-Dependent and Predicts Immunomodulation in Splenocytes. 2019 , 20, 2115-2122	3
451	Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. 2019 , 303, 130-150	80
450	TLR7 Controls VSV Replication in CD169 SCS Macrophages and Associated Viral Neuroinvasion. 2019 , 10, 466	4
449	Impact of Locally Administered Carboxydextran-Coated Super-Paramagnetic Iron Nanoparticles on Cellular Immune Function. 2019 , 15, e1900224	7
448	Evaluation of size and dose effects of rChe a 3 allergen loaded PLGA nanoparticles on modulation of Th2 immune responses by sublingual immunotherapy in mouse model of rhinitis allergic. 2019 , 563, 282-292	12
447	Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine. 2019 , 141, 6509-6518	35

446	Polydopamine as the Antigen Delivery Nanocarrier for Enhanced Immune Response in Tumor Immunotherapy. 2019 , 5, 2330-2342	17
445	Immunogenicity and Immunodominance in Antibody Responses. 2020 , 428, 89-102	3
444	Harnessing Dendritic Cells for Poly (D,L-lactide--glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy. 2019 , 10, 707	23
443	Tumor microenvironment-responsive fluorogenic nanoprobe for ratiometric dual-channel imaging of lymph node metastasis. 2019 , 179, 9-16	11
442	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. 2019 , 8, e1801320	25
441	Drug Delivery for Cancer Immunotherapy and Vaccines. 2018 , 6, 232-244	13
440	Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. 2019 , 31, e1803322	107
439	Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines. 2019 , 10, 135	13
438	Biomimetic Nanomaterials from the Assembly of Polymers, Lipids, and Surfactants. 2019 ,	2
437	The Effect of Size, Dose, and Administration Route on Zein Nanoparticle Immunogenicity in BALB/c Mice. 2019 , 14, 9917-9928	12
436	Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets. 2019 , 9, 5797-5809	30
435	Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. 2019 , 14, 302-308	17
434	Design of polymeric nanocapsules to improve their lympho-targeting capacity. 2019 , 14, 3013-3033	7
433	Nanomaterials for Regenerative Medicine. 2019 ,	1
432	A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response. 2019 , 10, 2931	25
431	Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. 2019 , 85, 1-26	70
430	Next generation designer virus-like particle vaccines for dengue. 2019 , 18, 105-117	6
429	Engineering polymeric nanocapsules for an efficient drainage and biodistribution in the lymphatic system. 2019 , 27, 646-658	11

428	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. 2019 , 363, 649-654	138
427	Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. 2019 , 195, 23-37	77
426	M cell targeting engineered biomaterials for effective vaccination. 2019 , 192, 75-94	20
425	Biomimetic Nanoparticle Vaccines for Cancer Therapy. 2019 , 3, e1800219	50
424	Si-doping increases the adjuvant activity of hydroxyapatite nanorods. 2019 , 174, 300-307	9
423	Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. 2019 , 370, 715-724	27
422	A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization. 2019 , 13, 1116-1126	12
421	Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. 2019 , 20, 854-870	21
420	Tocopherol Emulsions as Functional Autoantigen Delivery Vehicles Evoke Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis. 2019 , 16, 607-617	5
419	Newcastle disease virus-like particles containing the Brucella BCSP31 protein induce dendritic cell activation and protect mice against virulent Brucella challenge. 2019 , 229, 39-47	2
418	Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. 2019 , 190-191, 111-120	31
417	Chitosan-based nanoparticles: An overview of biomedical applications and its preparation. 2019 , 49, 66-81	93
416	Poly(ethylene glycol)-alendronate coated nanoparticles for magnetic resonance imaging of lymph nodes. 2019 , 27, 659-669	4
415	Protein-based nanoparticles in cancer vaccine development. 2019 , 15, 164-174	69
414	Dendritic cells as cancer therapeutics. 2019 , 86, 77-88	38
413	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. 2019 , 141, 3-22	26
412	Biomimetic Nanotechnology toward Personalized Vaccines. 2020 , 32, e1901255	105
411	Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis. 2020 , 28, 55-69	24

410	Advances in nanomedical applications: diagnostic, therapeutic, immunization, and vaccine production. 2020 , 27, 19200-19213	63
409	Virus-like particles for vaccination against cancer. 2020 , 12, e1579	45
408	Current and New Approaches for Mucosal Vaccine Delivery. 2020 , 325-356	12
407	Nanotechnology platforms for cancer immunotherapy. 2020 , 12, e1590	45
406	Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice. 2020 , 35, 343-356	12
405	In-vitro and in-vivo comparison of rSAG1-loaded PLGA prepared by encapsulation and adsorption methods as an efficient vaccine against <i>Toxoplasma gondii</i> 2020 , 55, 101327	4
404	Development of nano-carriers for vaccine delivery. 2020 , 17, 167-187	7
403	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. 2020 , 240, 119742	29
402	Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy. 2020 , 2020, 9624532	18
401	Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV. 2019 , 12,	12
400	Delivered antigen peptides to resident CD8 ⁺ DCs in lymph node by micelle-based vaccine augment antigen-specific CD8 effector T cell response. 2020 , 147, 76-86	9
399	Recent Advances in Particulate Adjuvants for Cancer Vaccination. 2020 , 3, 1900115	7
398	A fast-dissolving microneedle array loaded with chitosan nanoparticles to evoke systemic immune responses in mice. 2020 , 8, 216-225	18
397	All the small things: How virus-like particles and liposomes modulate allergic immune responses. <i>European Journal of Immunology</i> , 2020 , 50, 17-32	6.1 9
396	Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. 2020 , 575, 118951	6
395	Engineering drug delivery systems to overcome mucosal barriers for immunotherapy and vaccination. 2020 , 8, 1695476	3
394	Critical design criteria for engineering a nanoparticulate HIV-1 vaccine. 2020 , 317, 322-335	11
393	Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?. 2019 , 12,	16

392	Parenterally Administered Porcine Epidemic Diarrhea Virus-Like Particle-Based Vaccine Formulated with CCL25/28 Chemokines Induces Systemic and Mucosal Immune Protectivity in Pigs. 2020 , 12,	2
391	Self-Assembled Cationic-Covered Nanoemulsion as A Novel Biocompatible Immunoadjuvant for Antiserum Production Against Scorpion Venom. 2020 , 12,	2
390	Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine. 2020 , 327, 533-545	11
389	PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity. 2020 , 33, 108258	10
388	Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines. 2020 , 5, 88	10
387	Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy. 2020 , 160, 19-35	9
386	Brave new world revisited: Focus on nanomedicine. 2020 , 533, 36-49	7
385	Tackling autoimmunity with nanomedicines. 2020 , 15, 1585-1597	22
384	A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. 2020 , 152, 105456	8
383	Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only. 2020 , 8,	5
382	Virus-like Particle Vaccines: A Prospective Panacea Against an Avian Influenza Panzootic. 2020 , 8,	2
381	Antitumour dendritic cell vaccination in a priming and boosting approach. 2020 , 19, 635-652	51
380	Past, Present, and Future of Anticancer Nanomedicine. 2020 , 15, 5719-5743	13
379	Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses. 2020 , 11, 1547	6
378	A REVIEW ON APPLICATION OF NANOADJUVANT AS DELIVERY SYSTEM. 2020 , 24-33	5
377	Cell and tissue engineering in lymph nodes for cancer immunotherapy. 2020 , 161-162, 42-62	22
376	Novel ssRNA phage VLP platform for displaying foreign epitopes by genetic fusion. 2020 , 38, 6019-6026	2
375	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. 2020 , 16, e1008665	25

374	Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy. 2020 , 7, 2001108	11
373	Potential for Targeting Myeloid Cells in Controlling CNS Inflammation. 2020 , 11, 571897	5
372	Vaccination Strategies Against Highly Variable Pathogens. 2020 ,	
371	Biosynthesis of Self-Assembled Proteinaceous Nanoparticles for Vaccination. 2020 , 32, e2002940	18
370	Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice. 2020 , 8,	3
369	Engineering Strategies for Lymph Node Targeted Immune Activation. 2020 , 53, 2055-2067	18
368	Chemical Strategies to Boost Cancer Vaccines. 2020 , 120, 11420-11478	29
367	Controlled Lengthwise Assembly of Helical Peptide Nanofibers to Modulate CD8 T-Cell Responses. 2020 , 32, e2003310	9
366	Size-Dependent Antibacterial Immunity of Protoplast-Derived Particulate Vaccines. 2020 , 15, 10321-10330	4
365	Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b. 2020 , 12,	2
364	Protein and Peptide Nanocluster Vaccines. 2021 , 433, 107-130	0
363	Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. 2020 , 12,	19
362	Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse. 2020 , 59, 14628-14638	19
361	TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. 2020 , 17, 2109-2124	15
360	The 3Ds in virus-like particle based-vaccines: "Design, Delivery and Dynamics". 2020 , 296, 155-168	22
359	The choice of anti-tumor strategies based on micromolecules or drug loading function of biomaterials. 2020 , 487, 45-52	5
358	Biogenic nanoparticles as immunomodulator for tumor treatment. 2020 , 12, e1646	12
357	Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy. 2020 , 399, 125854	15

356	Induction of Robust Immune Responses by CpG-ODN -Loaded Hollow Polymeric Nanoparticles for Antiviral and Vaccine Applications in Chickens. 2020 , 15, 3303-3318	10
355	pH-Responsive Biomimetic Polymeric Micelles as Lymph Node-Targeting Vaccines for Enhanced Antitumor Immune Responses. 2020 , 21, 2818-2828	14
354	A stable USPIO capable for MR lymphography with ultra-low effective dosage. 2020 , 29, 102233	2
353	Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma. 2020 , 49, 808-823	4
352	Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy. 2020 , 167, 78-88	27
351	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. 2020 , 108, 1455-1489	7
350	Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies. 2020 , 11, 969	15
349	Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse. 2020 , 132, 14736-14746	1
348	Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs. 2020 , 11, 1100	53
347	Immune cell engineering: opportunities in lung cancer therapeutics. 2020 , 10, 1203-1227	1
346	Mucosal Delivery of Drugs and Biologics in Nanoparticles. 2020 ,	4
345	Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity. 2020 , 38, 3455-3463	11
344	Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines. 2020 , 19, 235-246	4
343	Bacterial Membrane Vesicles. 2020 ,	2
342	Engineered Nanomaterials and Type I Allergic Hypersensitivity Reactions. 2020 , 11, 222	15
341	Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic. 2020 , 11, 24	15
340	Simple Nanoparticles from the Assembly of Cationic Polymer and Antigen as Immunoadjuvants. 2020 , 8,	11
339	Development of Different Methods for Preparing Outer Membrane Vesicles Vaccine: Impact of Preparation Method on Protective Efficacy. 2020 , 11, 1069	9

338	Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. 2020 , 12,	9
337	Cationic Nanostructures for Vaccines Design. 2020 , 5,	10
336	Engineered Ovalbumin Nanoparticles for Cancer Immunotherapy. 2020 , 3, 2000100	15
335	Controlling timing and location in vaccines. 2020 , 158, 91-115	55
334	Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. 2020 , 326, 297-309	24
333	Biomaterials for Immunoengineering. 2020 , 1199-1215	
332	Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells. 2020 , 15, 1021-1035	5
331	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. 2020 , 94,	8
330	Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines. 2020 , 12,	6
329	Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. 2020 , 38, 320-332	107
328	Modulation of immune responses with nanoparticles and reduction of their immunotoxicity. 2020 , 8, 1490-1501	28
327	Interaction of Nanomaterials with the Immune System. 2020 ,	0
326	The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution. 2020 , 17, 944-953	36
325	Factors That Govern the Induction of Long-Lived Antibody Responses. 2020 , 12,	11
324	Dendritic Cells as Targets for Biomaterial-Based Immunomodulation. 2020 , 6, 2726-2739	9
323	Immunostimulatory materials. 2020 , 471-497	
322	Nanoparticle Uptake in a Spontaneous and Immunocompetent Woodchuck Liver Cancer Model. 2020 , 14, 4698-4715	13
321	Linking autoantigen properties to mechanisms of immunity. 2020 , 165-166, 105-116	3

320	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. 2020 , 94,	18
319	Carbohydrate Conjugates in Vaccine Developments. 2020 , 8, 284	30
318	Virus-like particles: nano-carriers in targeted therapeutics. 2020 , 197-210	1
317	Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity. 2020 , 38, 3892-3901	9
316	Nanometer-Sized Aggregates Generated Using Short Solubility Controlling Peptide Tags Do Increase the Immunogenicity of a Nonimmunogenic Protein. 2020 , 17, 1629-1637	7
315	Advancements in protein nanoparticle vaccine platforms to combat infectious disease. 2021 , 13, e1681	13
314	Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy. 2021 , 10, e2000845	15
313	Biomedical nanoparticle design: What we can learn from viruses. 2021 , 329, 552-569	14
312	Lymph-directed nitric oxide increases immune cell access to lymph-borne nanoscale solutes. 2021 , 265, 120411	7
311	Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils. 2021 , 329, 955-970	4
310	extracellular vesicles: exploitation for vaccine technology and diagnostic methods. 2021 , 47, 13-33	4
309	Polyphosphazene immunoadjuvants: Historical perspective and recent advances. 2021 , 329, 299-315	8
308	Functionalized multifunctional nanovaccine for targeting dendritic cells and modulation of immune response. 2021 , 593, 120123	6
307	Uptake and trafficking of different sized PLGA nanoparticles by dendritic cells in imiquimod-induced psoriasis-like mice model. 2021 , 11, 1047-1055	7
306	Polymeric nanoparticle vaccines to combat emerging and pandemic threats. 2021 , 268, 120597	35
305	Inducing immune tolerance with dendritic cell-targeting nanomedicines. 2021 , 16, 37-46	46
304	Protein-based nanomaterials and nanosystems for biomedical applications: A review. 2021 , 43, 166-184	17
303	Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. 2021 , 1, 2000041	9

302	Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides. 2021 , 32, 102321	5
301	Nanoparticles in cancer immunotherapies: An innovative strategy. 2021 , 37, e3070	4
300	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. 2021 , 4, 2000147	0
299	The Use of Nanobiotechnology in Immunology and Vaccination. 2021 , 9,	5
298	Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics. 2020 , 8, 631351	4
297	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. 2021 , 12, 324	32
296	Health and safety hazards of nanomaterials. 2021 , 223-240	1
295	Bio inspired materials for nonviral vaccine delivery. 2021 , 139-170	
294	Enhancing subcutaneous injection and target tissue accumulation of nanoparticles via co-administration with macropinocytosis inhibitory nanoparticles (MiNP). 2021 , 6, 393-400	4
293	Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. 2021 , 19, 59	72
292	The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. 2021 , 330, 305-316	16
291	The Revolutionary Roads to Study Cell-Cell Interactions in 3D In Vitro Pancreatic Cancer Models. 2021 , 13,	8
290	Engineering Nano-Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment.. 2021 , 5, e2001191	7
289	Recent Advances on Nanotechnology-Based Strategies for Prevention, Diagnosis, and Treatment of Coronavirus Infections. 2021 , 2021, 1-20	10
288	The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration. 2021 , 9,	0
287	Design of Polymeric Carriers for Intracellular Peptide Delivery in Oncology Applications. 2021 , 121, 11653-11698	8
286	Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. 2021 , 13,	47
285	Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances. 2021 , 13,	6

284	Humoral and cell-mediated immune responses to plant-produced African horse sickness virus VP7 quasi-crystals. 2021 , 294, 198284	0
283	The impact of size on particle drainage dynamics and antibody response. 2021 , 331, 296-308	10
282	Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. 2021 , 12, 641307	12
281	Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. 2021 , 10, e2002142	18
280	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. 2021 , 2, 243-262.e8	25
279	Pollen-Mimetic Metal-Organic Frameworks with Tunable Spike-Like Nanostructures That Promote Cell Interactions to Improve Antigen-Specific Humoral Immunity. 2021 , 15, 7596-7607	5
278	Role of nanostructures in allergy: Diagnostics, treatments and safety. 2021 , 76, 3292-3306	2
277	Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection. 2021 , 21, 2476-2486	5
276	Formulation of stabilizer-free, nontoxic PLGA and elastin-PLGA nanoparticle delivery systems. 2021 , 597, 120340	5
275	Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env. 2021 , 9,	2
274	Hepatitis B core-based virus-like particles: A platform for vaccine development in plants. 2021 , 29, e00605	4
273	A review article on nanotechnology in aquaculture sustainability as a novel tool in fish disease control. 2021 , 29, 1-22	13
272	Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy.	
271	Photochemical internalization (PCI)-mediated activation of CD8 T cells involves antigen uptake and CCR7-mediated transport by migratory dendritic cells to draining lymph nodes. 2021 , 332, 96-108	4
270	Aliphatic Polyester-Based Materials for Enhanced Cancer Immunotherapy. 2021 , 21, e2100087	2
269	Molecular tracking devices quantify antigen distribution and archiving in the murine lymph node. 2021 , 10,	3
268	Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges. 2021 , 13, 491-507	4
267	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection.	2

266	Effect of physicochemical properties on fate of nanoparticle-based cancer immunotherapies. 2021 , 11, 886-902	8
265	Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses. 2021 , 206, 1806-1816	2
264	Peptide-based supramolecular vaccine systems. 2021 , 133, 153-167	8
263	Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems. 2021 , 9,	1
262	Characteristics of immune induction by transcutaneous vaccination using dissolving microneedle patches in mice. 2021 , 601, 120563	1
261	Preclinical models and technologies to advance nanovaccine development. 2021 , 172, 148-182	3
260	Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions. 2021 , 10, e2100299	4
259	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. 2021 , 13,	7
258	Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines. 2021 , 9,	13
257	Structure and Immune Function of Afferent Lymphatics and Their Mechanistic Contribution to Dendritic Cell and T Cell Trafficking. 2021 , 10,	4
256	A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics. 2021 , 10,	2
255	Black phosphorous nanosheet: A novel immune-potentiating nanoadjuvant for near-infrared-improved immunotherapy. 2021 , 273, 120788	13
254	Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. 2021 , 9,	2
253	Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers. 2021 , 12, 684612	2
252	Nanomedicine at the crossroads - A quick guide for IVIVC. 2021 , 179, 113829	7
251	Nano-Microparticle Platforms in Developing Next-Generation Vaccines. 2021 , 9,	8
250	Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. 2021 , 38,	36
249	Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. 2021 , 335, 237-246	27

248	Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. 2021 , 11,	9
247	Contributions of PD-L1 reverse signaling to dendritic cell trafficking. 2021 ,	1
246	Preparation of hydrophobically modified carboxylated pullulan nanoparticles for evaluating the effect of hydrophobic substitution on the properties and functions of nanoparticles. 1-11	0
245	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. 2021 , 11, 14494	2
244	Synopsis of Pharmotechnological Approaches in Diagnostic and Management Strategies for Fighting Against COVID-19. 2021 , 27, 4086-4099	0
243	GMMA-Based Vaccines: The Known and The Unknown. 2021 , 12, 715393	3
242	Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity. 2021 , 22,	3
241	Preparation and evaluation of virus-like particle vaccine against H3N8 subtype equine influenza. 2021 , 157, 104885	0
240	Precision Wormlike Nanoadjuvant Governs Potency of Vaccination. 2021 , 21, 7236-7243	2
239	Vaccine delivery systems toward lymph nodes. 2021 , 179, 113914	9
238	A systematic assessment of the relationship between synthetic surfactants and mucosal adjuvanticity. 2021 , 165, 113-126	0
237	Advances in technology and applications of nanoimmunotherapy for cancer. 2021 , 9, 63	1
236	Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies. 2021 ,	2
235	Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. 2021 , 275, 120868	4
234	Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A. 2021 , 7, 2723-2735	1
233	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. 2021 , 131, 16-40	34
232	Designing spatial and temporal control of vaccine responses. 2021 , 1-22	16
231	Chitosan nanoparticle formulation attenuates poly (I:C) induced innate immune responses against inactivated virus vaccine in Atlantic salmon (<i>Salmo salar</i>). 2021 , 40, 100915	0

230	Sentinel lymph node detection by combining nonradioactive techniques with contrast agents: State of the art and prospects. 2021 , e202100149	0
229	Nanotechnology-empowered vaccine delivery for enhancing CD8 T cells-mediated cellular immunity. 2021 , 176, 113889	6
228	Nanovaccine: an emerging strategy. 2021 , 20, 1273-1290	7
227	The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases. 2021 , 339, 274-283	0
226	Tolerogenic vehicles of antigens in the antigen-specific immunotherapy for autoimmunity. 2021 , 65, 102772	0
225	Bifunctional lipids in tumor vaccines: An outstanding delivery carrier and promising immune stimulator. 2021 , 608, 121078	0
224	Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. 2021 , 177, 113927	6
223	Immunological perspectives on spatial and temporal vaccine delivery. 2021 , 178, 113966	0
222	Delivery strategies for cancer vaccines and immunoadjuvants. 2022 , 359-408	1
221	Synergistic enhancement of immunological responses triggered by hyperthermia sensitive Pt NPs NIR laser to inhibit cancer relapse and metastasis. 2022 , 7, 389-400	9
220	pDNA and mRNA vaccines. 2022 , 157-205	0
219	Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead. 2021 , 10,	6
218	Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites. 2021 , 433, 77-106	4
217	Biocompatible Lipid Polymer Cationic Nanoparticles for Antigen Presentation. 2021 , 13,	6
216	Influenza Virosomes as Antigen Delivery System. 2013 , 287-307	3
215	Nanostability. 2014 , 57-95	6
214	Transcutaneous Immunization Using Nano-sized Drug Carriers. 2016 , 349-367	2
213	Respiratory Drug/Vaccine Delivery Using Nanoparticles. 2020 , 125-154	1

212	Bacterial Membrane Vesicles and Their Applications as Vaccines and in Biotechnology. 2020 , 219-251	1
211	Intralymphatic Vaccination. 2012 , 205-221	1
210	The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems. 2021 , 89, 1364-1372	2
209	Self-assembled particulate vaccine elicits strong immune responses and reduces <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> infection in mice. 2020 , 10, 22289	2
208	Immunological basis for enhanced immunity of nanoparticle vaccines. 2019 , 18, 269-280	65
207	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.	4
206	Immune response to vaccine candidates based on different types of nanoscaffolded RBD domain of the SARS-CoV-2 spike protein.	5
205	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.	3
204	Next generation vaccines: single-dose encapsulated vaccines for improved global immunisation coverage and efficacy. 2015 , 67, 400-8	15
203	Identification of BALB/c Immune Markers Correlated with a Partial Protection to <i>Leishmania infantum</i> after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine. 2017 , 11, e0005311	30
202	Quantum dots for tracking dendritic cells and priming an immune response in vitro and in vivo. 2008 , 3, e3290	61
201	Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. 2010 , 5, e9784	70
200	Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. 2012 , 7, e43248	22
199	Protective antibody and CD8+ T-cell responses to the <i>Plasmodium falciparum</i> circumsporozoite protein induced by a nanoparticle vaccine. 2012 , 7, e48304	79
198	Size-dependent antimicrobial effects of novel palladium nanoparticles. 2014 , 9, e85981	147
197	Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. 2017 , 12, e0181403	5
196	DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against <i>Leptospira</i> lethal infection. 2020 , 115, e190396	3
195	Current applications and future prospects of nanotechnology in cancer immunotherapy. 2019 , 16, 486-497	24

194	Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines. 2019 , 25, 1443-1454	20
193	Recognition Sites for Cancer-targeting Drug Delivery Systems. 2019 , 20, 815-834	5
192	Designing the optimal vaccine: the importance of cytokines and dendritic cells. 2010 , 3, 7-17	14
191	Nanotechnology-Based Vaccines for Allergen-Specific Immunotherapy: Potentials and Challenges of Conventional and Novel Adjuvants under Research. 2020 , 8,	16
190	Interaction of Immune System Protein with PEGylated and Un-PEGylated Polymeric Nanoparticles. 2017 , 06, 103-113	3
189	Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo. 2015 , 4,	50
188	Nanoparticle Systems Applied for Immunotherapy in Various Treatment Modalities. 2021 , 117-142	
187	The New Frontier in Medicine at the Convergence of Nanotechnology and Immunotherapy. 2021 , 3-27	
186	Cellular uptake of polylactide particles induces size dependent cytoskeletal remodeling in antigen presenting cells. 2021 , 9, 7962-7976	2
185	Association of a vaccine adjuvant with endogenous HDL increases lymph uptake and dendritic cell activation. 2021 ,	1
184	NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma. 2021 , 11, 754541	3
183	Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy. 2021 , 13,	5
182	Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. 2021 , 610, 121212	4
181	Lymphatic transport system to circumvent hepatic metabolism for oral delivery of lipid-based nanocarriers. 2021 , 66, 102934	2
180	Perspectives on Nanotechnology. 102-117	
179	Design and Development of Recombinant Vaccines with Viral Properties. 19-63	
178	Augmenting the Skin Immune System. 2013 , 151-164	
177	Cancer Vaccines: Fundamentals and Strategies. 2014 , 163-185	

- 176 Functional Nanoparticles for Vaccine Delivery Systems. **2014**, 205-228
- 175 Applications of Nanomaterials for Activation and Suppression of Immune Responses. **2015**, 205-220
- 174 Vaccines to Program Protective Humoral Immunity. **2016**, 275-278
- 173 Aliphatic Polyesters: Particulate Vaccine Delivery. 147-185
- 172 Immunotherapy and Vaccines. **2016**, 441-464
- 171 Emission of CdTe Nanocrystals Coupled to Microcavities. **2016**, 133-184
- 170 Applications of Nanomaterials for Activation and Suppression of Immune Responses. **2017**, 859-875
- 169 Chapter 9: Update on Nanoparticle-Mediated Immune Mechanisms for Dendritic Cell-Based Targeted Immunity and Cancer. **2017**, 235-264
- 168 Nano/Microparticles for Retina and Posterior Diseases. **2018**, 107-130
- 167 Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. **2019**, 551-600
- 166 Immunomodulatory Nanomaterials. **2019**, 119-142 0
- 165 Drug Delivery Strategies for Tolerogenic Therapy for Autoimmune Diseases in an Antigen-Specific Manner. **2019**, 112-140
- 164 Molecular tracking devices quantify antigen distribution and archiving in the lymph node.
- 163 Dense poly(ethylene glycol) coatings maximize nanoparticle transport across lymphatic endothelial cells. 1
- 162 Design, production and immunomodulatory potency of a novel allergen bioparticle. **2020**, 15, e0242867 1
- 161 Impact of Nanoparticles on Dendritic Cells. **2020**, 73-82 0
- 160 Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials. **2020**, 177-204
- 159 Challenges and Future Perspectives of Nanotoxicology. **2020**, 451-466 1

158	Self-Assembling Peptides for Vaccine Development and Antibody Production. 2020 , 1497-1517	
157	Nanopartikel für AEr.	
156	Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer Immunotherapy. 2021 , 21, 9410-9418	6
155	Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants. 2021 , 13,	2
154	Drug Delivery Strategies for Tolerogenic Therapy for Autoimmune Diseases in an Antigen-Specific Manner. 23-51	
153	The impact of size on particle drainage dynamics and antibody response.	
152	A self-assembled protein nanoparticle serving as a one-shot vaccine carrier.	
151	Nanoparticle vaccines against respiratory syncytial virus. 2020 , 15, 763-778	2
150	Proof of Concept Study: Mesoporous Silica Nanoparticles, From Synthesis to Active Specific Immunotherapy. 2020 , 2,	1
149	Development of cancer vaccine adjuvant using CpG-DNA and polysaccharide carrier. 2020 , 35, 448-449	
148	Non-invasive administration of biodegradable nano-carrier vaccines. 2017 , 9, 15-35	13
147	Dendritic cell engineering for selective targeting of female reproductive tract cancers. 2018 , 148, S50-S63	1
146	Virus-like particle-based vaccines against SARS-CoV-2. 2022 , 173-192	0
145	Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy. 2021 , 341, 184-205	1
144	Synthesis of silica nanoparticles for biological applications. 2022 , 377-412	0
143	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease.	1
142	Innovations in lymph node targeting nanocarriers. 2021 , 101534	2
141	Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus. 2021 , 9,	3

140	Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. 2021 , 19, 389	5
139	Whole-Cell-Mimicking Carrier-Free Nanovaccines Amplify Immune Responses Against Cancer and Bacterial Infection. 2108917	1
138	Oligonucleotide delivery to antigen presenting cells by using schizophyllan.. 2021 , 42, 100434	0
137	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy.. 2022 , 342, 210-227	1
136	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.. 2022 , 38, 110217	1
135	Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.. 2022 ,	3
134	Understanding StructureFunction Relationships of Nanoadjuvants for Enhanced Cancer Vaccine Efficacy. 2111670	3
133	Nanotechnology for cancer theranostics. 2022 , 19-36	
132	Copper nanoparticles: Synthesis, characterization, and its veterinary applications. 2022 , 507-534	
131	Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.. 2022 , 60, 335	2
130	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.. 2022 , 110318	2
129	Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.. 2022 , 10,	3
128	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. 2021 ,	16
127	evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy.. 2022 ,	1
126	Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. 2022 , 129-148	
125	Nano dimensions/adjuvants in COVID-19 vaccines.. 2022 ,	1
124	Next generation self-replicating RNA vectors for vaccines and immunotherapies.. 2022 ,	0
123	Liposomes as Adjuvants and Vaccine Delivery Systems.. 2022 , 16, 1-20	2

122	Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2.	0
121	Construction of Orthogonal Modular Proteinaceous Nanovaccine Delivery Vectors Based on mSA-Biotin Binding.. 2022 , 12,	3
120	Nanoparticle therapy for head and neck cancers.. 2022 ,	
119	Artificial Nanoplatelets Depend on Size for Precisely Inducing Thrombosis in Tumor Vessels.. 2022 , e2101474	
118	Biological Nanoparticles in Vaccine Development.. 2022 , 10, 867119	1
117	Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases.. 2022 , 13, 864403	0
116	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.. 2022 , 132,	2
115	Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans.. 2022 , 3, 832010	1
114	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.. 2022 , e2200027	3
113	Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines.. 2021 , e2107946	0
112	Bionized Nanoferrite Particles Alter the Course of Experimental Cryptococcus neoformans Pneumonia.. 2022 , e0239921	0
111	Precision design of engineered nanomaterials to guide immune systems for disease treatment. 2022 , 5, 1162-1191	0
110	Nanoparticles with dense poly(ethylene glycol) coatings with near neutral charge are maximally transported across lymphatics and to the lymph nodes.. 2022 ,	2
109	Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases.. 2022 , 10, 889291	1
108	Bionized nanoferrite particles alter the course of experimental Cryptococcus neoformans pneumonia.	
107	Amphiphilic Cyclodextrin-Based Nanoparticulate Vaccines Can Trigger T-Cell Immune Responses. 2022 , 2, 2100082	0
106	Supramolecular Nanostructures for Vaccines.. 2021 , 7,	1
105	Cationic Nanostructures as Adjuvants for Vaccines.. 2022 , 2412, 233-245	1

104	Bacterial Lymphatic Metastasis in Infection and Immunity.. 2021 , 11,	1
103	Current view on novel vaccine technologies to combat human infectious diseases. 2021 , 106, 25	6
102	Platform Technologies Based on Virus-Like Particles (VLPs) for Infectious Diseases. 2022 , 541-553	
101	Nano toolbox in immune modulation and nanovaccines.. 2022 ,	1
100	Data_Sheet_1.docx. 2018 ,	
99	Data_Sheet_1.docx. 2019 ,	
98	Data_Sheet_1.docx. 2020 ,	
97	Data_Sheet_1.pdf. 2019 ,	
96	Image_1.tiff. 2018 ,	
95	Image_2.tiff. 2018 ,	
94	Image_3.tiff. 2018 ,	
93	Video_1.MOV. 2018 ,	
92	Data_Sheet_1.pdf. 2020 ,	
91	Data_Sheet_1.PDF. 2020 ,	
90	"Nano-ghosts": Risk assessment of submicron-sized particles in food biased towards fictional "nano".. 2022 , 21, 279-299	
89	Development of an Antigen Delivery System for a B Cell-Targeted Vaccine as an Alternative to Dendritic Cell-Targeted Vaccines.. 2022 , 70, 341-350	
88	In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4 and CD8 T-cell epitopes for cancer immunotherapy.. 2022 ,	0
87	Trafficking and retention of protein antigens across systems and immune cell types.. 2022 , 79, 275	2

86	Nano-bio interactions: A major principle in the dynamic biological processes of nano-assemblies.. 2022 , 186, 114318	0
85	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.. 2022 , 347, 175-182	0
84	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. 2022 , 7,	1
83	Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants. 2022 , 13,	0
82	Rapid Development of a Mucosal Nanoparticle Flu Vaccine by Genetic Engineering of Bacteriophage T4 using CRISPR-Cas.	
81	Nanomaterials and immune system. 2022 , 65-114	
80	Development of novel vaccines using nanomaterials against COVID-19. 2022 , 329-345	
79	Nanovaccines against viral infections: Current trends and future prospects. 2022 , 315-328	0
78	Dual-Responsive Nanovaccine for Cytosolic Delivery of Antigens to Boost Cellular Immune Responses and Cancer Immunotherapy. 2022 ,	
77	A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. 2022 , 102584	1
76	The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination. 2022 , 10, 1119	0
75	Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. 2022 , 188, 114417	2
74	Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. 2200756	2
73	Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic. 20210082	0
72	Across-Cancer Immune Responses Induced by Nanovaccines or Microvaccines to Prevent Different Cancers and Cancer Metastasis.	
71	Progress towards the Development of a Universal Influenza Vaccine. 2022 , 14, 1684	0
70	Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates. 13,	0
69	Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review. 2022 , 14, 1782	0

68	DNA Origami Presenting the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Response.	0
67	Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2. 2022 ,	0
66	Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. 2022 , 349, 844-875	2
65	Nanoimmunoengineering strategies in cancer diagnosis and therapy.	0
64	A proposed mathematical description of in vivo nanoparticle delivery. 2022 , 189, 114520	1
63	Adjuvants, the Elephant in the Room for RNA Vaccines. 2022 , 257-276	0
62	Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression.	0
61	Short term, low dose alpha-ketoglutarate based polymeric nanoparticles with methotrexate reverse rheumatoid arthritis symptoms in mice and modulate T helper cell responses.	0
60	Messenger RNA for Prophylaxis. 2022 , 17-40	0
59	A brief go-to on the epidemiology of Malaria and the usage of virus like particles (VLPs) as a novel immunogenic vaccine platform. 2022 , 3, 4-16	0
58	Novel Proteoliposome-Based Vaccine against E. coli: A Potential New Tool for the Control of Bovine Mastitis. 2022 , 12, 2533	0
57	Tumor-Targeted Polydopamine-Based Nanoparticles for Multimodal Mapping Following Photothermal Therapy of Metastatic Lymph Nodes. Volume 17, 4659-4675	0
56	Bet α -1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Bet α -1 in a murine immunogenicity model. 13,	0
55	How promising are HIV-1-based virus-like particles for medical applications. 12,	0
54	Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse.	1
53	Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology. 2022 , 14, 2291	0
52	Long-Term Vaccine Delivery and Immunological Responses Using Biodegradable Polymer-Based Carriers.	0
51	Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds. 2022 , 10, 1920	2

- 50 Across-cancer immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis. **2022**, 105511 ○
- 49 Innate immune mechanisms of mRNA vaccines. **2022**, 55, 1993-2005 4
- 48 Penetration and Translocation of Functional Inorganic Nanomaterials into Biological Barriers. **2022**, 114615 1
- 47 Polymer-colloidal systems as MRI-detectable nanocarriers for peptide vaccine delivery. **2022**, 181, 111704 ○
- 46 Mannosylated Polycations Target CD206+ Antigen-Presenting Cells and Mediate T-Cell-Specific Activation in Cancer Vaccination. ○
- 45 Protein-based nanocages for vaccine development. **2023**, 353, 767-791 ○
- 44 Trojan horse nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escaping. ○
- 43 Polymeric nanoparticle-based nanovaccines for cancer immunotherapy. ○
- 42 Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy. **2022**, 23, 14975 ○
- 41 Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delivering mRNA and Preventing Cancer. ○
- 40 Virus-like Particles for TEM Regulation and Antitumor Therapy. **2022**, 13, 304 ○
- 39 Lipid Nanoparticles Technology in Vaccines; Shaping the Future of Prophylactic Medicine. **2022**, 113111 ○
- 38 Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine. ○
- 37 Immunomodulatory nano-preparations for rheumatoid arthritis. **2023**, 30, 9-19 ○
- 36 Osmotic Pressure as Driving Force for Reducing the Size of Nanoparticles in Emulsions. ○
- 35 Particle-Based therapies for antigen specific treatment of type 1 diabetes. **2023**, 631, 122500 ○
- 34 Role of Supramolecules in Vaccine Development. **2022**, 301-317 ○
- 33 Metal-organic coordination polymers for delivery of immunomodulatory agents, and infectious disease and cancer vaccines. ○

- 32 Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response. ○
- 31 Bioresponsive Immunotherapeutic Materials. 2209778 ○
- 30 Mycobacterium avium subsp. paratuberculosis antigens induce cellular immune responses in cattle without causing reactivity to tuberculin in the tuberculosis skin test. 13, ○
- 29 Nanoparticle-Conjugated TLR9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines. ○
- 28 Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application. ○
- 27 Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis. **2023**, 579, 46-53 ○
- 26 Nanomaterials and Advances in Tumor Immune-Related Therapy: A Bibliometric Analysis. **2022**, 18, 2154-2170 ○
- 25 A thermally stable protein nanoparticle that stimulates long lasting humoral immune response. ○
- 24 Phage Vaccines and Phage Therapy. **2011**, 245-258 ○
- 23 Vaccines: An overview. **2023**, 699-717 ○
- 22 pH-Sensitive and Biodegradable $Mn_3(PO_4)_2 \cdot 3H_2O$ Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 Vaccine to Induce Potent and Broad-Spectrum Immunity. 1
- 21 Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines. **2023**, 236, 123979 ○
- 20 Supramolecular Polyphenol-DNA Microparticles for In Vivo Adjuvant and Antigen Co-Delivery and Immune Stimulation. **2023**, 62, ○
- 19 Supramolecular Polyphenol-DNA Microparticles for In Vivo Adjuvant and Antigen Co-Delivery and Immune Stimulation. **2023**, 135, ○
- 18 Virus-like nanoparticles as enzyme carriers for Enzyme Replacement Therapy (ERT). **2023**, 580, 73-87 ○
- 17 Holistic View on the Structure of Immune Response: Petri Net Model. **2023**, 11, 452 ○
- 16 Platforms, advances, and technical challenges in virus-like particles-based vaccines. 14, ○
- 15 Molecular Bottlebrushes for Immunostimulatory CpG ODN Delivery: Relationship among Cation Density, Complex Formation Ability, and Cytotoxicity. **2023**, 24, 1299-1309 ○

- 14 A Thermal-Stable Protein Nanoparticle That Stimulates Long Lasting Humoral Immune Response. **2023**, 11, 426 ○
- 13 Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses. 2202595 ○
- 12 Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. 14, ○
- 11 Current Status and Prospects of Vaccines based on DDS Technology. **2022**, 37, 402-411 ○
- 10 Effect of Antigen Structure in Subunit Vaccine Nanoparticles on Humoral Immune Responses. **2023**, 9, 1296-1306 ○
- 9 Tilapia lake virus disease: Vaccine strategies to control the threat to tilapia aquaculture. ○
- 8 Site-Specific Modification of Virus-Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity. 2300125 ○
- 7 Enhancement of Immune Response of Bioconjugate Nanovaccine by Loading of CpG through Click Chemistry. **2023**, 13, 507 ○
- 6 DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response. **2023**, 6, ○
- 5 Nanovaccine. **2023**, 37-65 ○
- 4 Immunogenicity and protective efficacy of an inactivated Newcastle disease virus vaccine encapsulated in poly-(lactic-co-glycolic acid) nanoparticles. **2023**, 102679 ○
- 3 Nanoparticulates. **2023**, 797-838 ○
- 2 mRNA vaccination in breast cancer: current progress and future direction. ○
- 1 Biomimetic and bioinspired nano-platforms for cancer vaccine development. ○